The effect of hyoscine butylbromide on the duration and progress of labor in primigravidae: a randomized controlled trial: methodological issues

2017 ◽  
Vol 32 (6) ◽  
pp. 1049-1049
Author(s):  
Mehdi Ranjbaran
2014 ◽  
Vol 61 (6) ◽  
pp. 1049-1054 ◽  
Author(s):  
Oluwakemi Badaki-Makun ◽  
J. Paul Scott ◽  
Julie A. Panepinto ◽  
T. Charles Casper ◽  
Cheryl A. Hillery ◽  
...  

2019 ◽  
Vol 24 (Supplement_2) ◽  
pp. e44-e45 ◽  
Author(s):  
Naveen Poonai ◽  
Sharlene Elsie ◽  
Kriti Kumar ◽  
Kamary Coriolano ◽  
Shaily Brahmbhatt ◽  
...  

2020 ◽  
Vol 34 (3) ◽  
pp. 357-364
Author(s):  
Pedro Henrique Perim ◽  
André Barroso Heibel ◽  
Guilherme Giannini Artioli ◽  
Bruno Gualano ◽  
Bryan Saunders

Supplementation with β-alanine (BA) increases muscle carnosine content, although the amount of BA used for muscle carnosine loading has been suggested to be low. However, methodological issues may have underestimated the amount of BA used. The aim of this study was to determine the estimated amount of BA converted to muscle carnosine, using a retrospective analysis from a 4-week randomized controlled trial investigating the effects of BA supplementation on muscle carnosine content of the m. vastus lateralis. Twenty-five males (age 27±5 years, height 1.74±0.09 m, body mass 77.4±11.5 kg) were supplemented with 6.4 g·day-1 of BA (N=17) or placebo (PL; N=8) for 28 days. Pre- and postsupplementation participants provided a muscle biopsy subsequently analysed for carnosine content using HPLC. Data were analysed using mixed-models and Pearson’s correlations. Muscle carnosine content increased by +11.0±6.7 mmol·kg-1dm (P<0.0001) in BA, with no change in PL (P=0.99). The estimated amount of BA converted to muscle carnosine was 2.1±1.2% (Range: 0.5 to 4.5%) of the total dose ingested. Pearson’s correlations showed that pre-supplementation carnosine was correlated to post-supplementation carnosine in the BA group (r=0.65, r2=0.38, P=0.009), but not the absolute change in carnosine (r=-0.28, r2=0.08, P=0.28) or the amount of BA used (r=-0.31, r2=0.10, P=0.22). The estimated amount of ingested BA used for carnosine synthesis was extremely low following 4 weeks of BA supplementation at 6.4 g·day-1. Data suggest that very little of the BA ingested is used for muscle carnosine synthesis and highlights the potential for further work to optimise BA supplementation in humans.


2006 ◽  
Vol 36 (1) ◽  
Author(s):  
Barnett S. Meyers ◽  
Catherine Peasley-Miklus ◽  
Alastair J. Flint ◽  
Benoit H. Mulsant ◽  
Anthony J. Rothschild

2017 ◽  
Vol 31 (22) ◽  
pp. 2959-2964 ◽  
Author(s):  
Ahmed Mohamed Maged ◽  
Medhat Mosaad ◽  
Ahmed M. AbdelHak ◽  
Mohamed M. Kotb ◽  
Maged M. Salem

2020 ◽  
Vol 34 (3) ◽  
pp. 357-364
Author(s):  
Pedro Henrique Perim ◽  
André Barroso Heibel ◽  
Guilherme Giannini Artioli ◽  
Bruno Gualano ◽  
Bryan Saunders

Supplementation with β-alanine (BA) increases muscle carnosine content, although the amount of BA used for muscle carnosine loading has been suggested to be low. However, methodological issues may have underestimated the amount of BA used. The aim of this study was to determine the estimated amount of BA converted to muscle carnosine, using a retrospective analysis from a 4-week randomized controlled trial investigating the effects of BA supplementation on muscle carnosine content of the m. vastus lateralis. Twenty-five males (age 27±5 years, height 1.74±0.09 m, body mass 77.4±11.5 kg) were supplemented with 6.4 g·day-1 of BA (N=17) or placebo (PL; N=8) for 28 days. Pre- and postsupplementation participants provided a muscle biopsy subsequently analysed for carnosine content using HPLC. Data were analysed using mixed-models and Pearson’s correlations. Muscle carnosine content increased by +11.0±6.7 mmol·kg-1dm (P<0.0001) in BA, with no change in PL (P=0.99). The estimated amount of BA converted to muscle carnosine was 2.1±1.2% (Range: 0.5 to 4.5%) of the total dose ingested. Pearson’s correlations showed that pre-supplementation carnosine was correlated to post-supplementation carnosine in the BA group (r=0.65, r2=0.38, P=0.009), but not the absolute change in carnosine (r=-0.28, r2=0.08, P=0.28) or the amount of BA used (r=-0.31, r2=0.10, P=0.22). The estimated amount of ingested BA used for carnosine synthesis was extremely low following 4 weeks of BA supplementation at 6.4 g·day-1. Data suggest that very little of the BA ingested is used for muscle carnosine synthesis and highlights the potential for further work to optimise BA supplementation in humans.


2020 ◽  
Vol 192 (48) ◽  
pp. E1612-E1619
Author(s):  
Naveen Poonai ◽  
Kriti Kumar ◽  
Kamary Coriolano ◽  
Graham Thompson ◽  
Shaily Brahmbhatt ◽  
...  

2020 ◽  
Vol 29 (1S) ◽  
pp. 412-424
Author(s):  
Elissa L. Conlon ◽  
Emily J. Braun ◽  
Edna M. Babbitt ◽  
Leora R. Cherney

Purpose This study reports on the treatment fidelity procedures implemented during a 5-year randomized controlled trial comparing intensive and distributed comprehensive aphasia therapy. Specifically, the results of 1 treatment, verb network strengthening treatment (VNeST), are examined. Method Eight participants were recruited for each of 7 consecutive cohorts for a total of 56 participants. Participants completed 60 hr of aphasia therapy, including 15 hr of VNeST. Two experienced speech-language pathologists delivered the treatment. To promote treatment fidelity, the study team developed a detailed manual of procedures and fidelity checklists, completed role plays to standardize treatment administration, and video-recorded all treatment sessions for review. To assess protocol adherence during treatment delivery, trained research assistants not involved in the treatment reviewed video recordings of a subset of randomly selected VNeST treatment sessions and completed the fidelity checklists. This process was completed for 32 participants representing 2 early cohorts and 2 later cohorts, which allowed for measurement of protocol adherence over time. Percent accuracy of protocol adherence was calculated across clinicians, cohorts, and study condition (intensive vs. distributed therapy). Results The fidelity procedures were sufficient to promote and verify a high level of adherence to the treatment protocol across clinicians, cohorts, and study condition. Conclusion Treatment fidelity strategies and monitoring are feasible when incorporated into the study design. Treatment fidelity monitoring should be completed at regular intervals during the course of a study to ensure that high levels of protocol adherence are maintained over time and across conditions.


Sign in / Sign up

Export Citation Format

Share Document